Arca
Skip to content
Tools
Tools

PPARD: Peroxisome proliferator-activated receptor delta

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Ligand-activated transcription factor key mediator of energy metabolism in adipose tissues.

  • Drugs that act on it: 8
  • Approved: 2
  • In phases 1 to 3: 6
  • Sponsors: 5

Who Is On It, and How Far Along

Every drug ChEMBL records acting on PPARD, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Other

Approved2

  • Elafibranor
  • Seladelpar

Phase 31

  • Fonadelpar

Phase 22

  • DB959
  • GW501516

Phase 13

  • AVE0847
  • CER-002
  • KD3010

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Senju Pharmaceutical Co., Ltd.113%
  • T3D Therapeutics, Inc.113%

Modalities

Drugs on this target by ChEMBL molecule type.

  • Small molecule450%
  • Other450%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Peroxisome proliferator-activated receptor delta agonist.
ElafibranorApprovedIpsenSmall moleculeAgonist—9—
SeladelparApprovedGilead SciencesSmall moleculeAgonist—7—
FonadelparPhase 3Senju Pharmaceutical Co., Ltd.Small moleculeAgonist—0—
DB959Phase 2T3D Therapeutics, Inc.OtherAgonist—0—
GW501516Phase 2GSKSmall moleculeAgonist—0—
AVE0847Phase 1—OtherAgonist—0—
CER-002Phase 1—OtherAgonist—0—
KD3010Phase 1—OtherAgonist—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 14 in all, from ClinicalTrials.gov.
A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting ElafibranorElafibranor—Not yet recruitingIpsen2026-10-30
Study of Seladelpar and Cilofexor in Participants With Primary Biliary CholangitisSeladelparPhase 2RecruitingGilead Sciences2026-09-25
Patients With Primary Biliary Cholangitis(PBC)Elafibranor, Seladelpar—Active, not recruitingFondazione Policlinico Universitario Agostino Gemelli IRCCS2026-06-05
Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During PregnancyElafibranor—RecruitingIpsen2026-04-29
Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life SettingSeladelpar—Not yet recruitingUniversity of Leipzig2026-04-24
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisElafibranorPhase 3RecruitingIpsen2026-02-04
Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).SeladelparPhase 2Not yet recruitingUniversity of California, San Diego2025-12-26
Monitoring the Response of Combination Ursodiol and Seladelpar TreatmentSeladelpar—Not yet recruitingMethodist Health System2025-08-14
A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)ElafibranorPhase 3Active, not recruitingIpsen2024-12-12
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing TreatmentElafibranor—Active, not recruitingIpsen2024-06-06
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisSeladelparPhase 3RecruitingGilead Sciences2023-09-25
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary CholangitisElafibranorPhase 3RecruitingIpsen2023-08-30
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.ElafibranorPhase 2Active, not recruitingIpsen2022-11-25
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)SeladelparPhase 3Active, not recruitingGilead Sciences2017-10-04

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Neurodegenerative disease
0.44
Type 2 diabetes mellitus
0.40
Familial hyperlipidemia
0.40
Cardiovascular disorder
0.38
Cholangitis
0.37
Esophageal disorder
0.31
Abnormality of the skeletal system
0.28

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
PPARD

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3979, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q03181, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.